Fig. 3.
Potential novel therapies in SSc
Digital ischaemia underlies important complications of systemic sclerosis and is amenable to multifaceted treatment including an increasing number of potentially disease-modifying agents that may work through a combination of vasodilator, anti-infective or structural vascular mechanisms. ETA: endothelin A; ETB: endothelin B; IP: prostacyclin; CD20: cluster of differentiation 20; CTLA4: cytotoxic T lymphocyte antigen 4; c-ABL: Abelson murine leukaemia viral oncogene; c-KIT: stem cell factor; CTGF: connective tissue growth factor; FGF: fibroblast growth factor; LPA: lysophosphatidic acid receptor; CB2: cannabinoid receptor 2; HT: 5-hydroxytryptamine receptor.